AdAlta Ltd (ASX:1AD) CEO Tim Oldham tells Proactive’s Elisha Newell that new data on lead drug candidate AD-214 favourably links preclinical animal studies and Phase I human trial results, providing important dose frequency insights as it moves through the clinic. The findings de-risk the I-body candidate’s future move into Phase 2 clinical trials and stand to boost confidence as AdAlta progresses partnership discussions. Oldham says the new data is “critically important” and a credit to AdAlta’s in-house scientific team.
AdAlta links AD-214 results with efficacy thanks to new data
